BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company's commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

Century Bancorp is a bank holding company. Through its subsidiary, Century Bank and Trust Company, the company provides services to commercial enterprises, state and local governments and agencies, non-profit organizations and individuals. The company also provides securities brokerage services through a program called Investment Services at Century Bank, which is supported by LPL Financial, a third party securities brokerage business. The company grants single-family and multi-family residential loans, commercial and commercial real estate loans, municipal loans, and a variety of consumer loans. In addition, the company provides savings accounts, NOW accounts, demand deposits, time deposits and money market accounts.

Eaton Vance is engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. Through its investment affiliates, the company manages active equity, income, alternative and blended strategies across a range of investment styles and asset classes, including United States, global and international equities, floating-rate bank loans, municipal bonds, global income, high-yield and investment grade bonds, and mortgage-backed securities, as well as a range of systematic investment strategies, including systematic equity, systematic alternatives and managed options strategies.

Five Prime Therapeutics is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The company's key product candidates are: FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 that it is studying in a clinical trial in multiple cancers; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that the company is studying in a clinical trial in multiple cancers; and Cabiralizumab (FPA008) is an antibody that the company and its partner Bristol-Myers Squibb Company, or BMS, are studying in clinical trials in multiple cancers in combination with BMS's PD-1 immune checkpoint inhibitor, Opdivo? (nivolumab).

Marchex is a call analytics company that helps businesses connect, drive, measure and convert callers into customers. The company's primary product offerings include: Marchex Call Analytics, which is an analytics platform for enterprises; Marchex Display and Video Analytics, which is a product for marketers that buy digital display advertising; Marchex Site Analytics, which is a product for marketers that can drive phone calls from websites; Marchex Social Analytics, which is a product for marketers that buy social media advertising; Marchex Call Marketplace, which is a mobile advertising network for businesses; and Local Leads, which is an advertising solution for small business resellers.

Oak Valley is a bank holding company. Through its subsidiary, Oak Valley Community Bank (the Bank), the company provides basic banking services to individuals and business enterprises in Oakdale, CA and the surrounding areas. The Bank provides a complement of business checking and savings accounts for its business customers. The Bank also provides commercial and real estate loans, as well as lines of credit. The Bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network.

Science Applications International provides technical, engineering and enterprise information technology (IT) services. The company provides engineering, systems integration and information technology offerings for government projects and provides a range of services with an emphasis on differentiated technology services. The company's offerings include: engineering; technology and equipment platform integration; maintenance of ground and maritime systems; logistics; training and simulation; operation and program support services; and end-to-end services spanning the design, development, integration, deployment, management and operations, sustainment and security of its customers' entire IT infrastructure.

Selecta Biosciences is a biopharmaceutical company using its ImmTOR? platform, designed to induce tolerance to biologic therapies that would otherwise be limited by immunogenicity to treat rare and serious diseases. The company's product candidate, SEL-212, is a combination of a therapeutic uricase enzyme (pegadricase) and its ImmTOR platform that is designed to control serum uric acid levels in patients with chronic refractory gout through monthly administration. The company is applying its ImmTOR platform to mitigate the formation of anti-drug antibodies when dosing gene therapy. The company's investigational gene therapy program targets the treatment of rare genetic diseases, including methylmalonic acidemia.